Company: MBIO
Filing Date: 2025-03-03
Form Type: DEF 14C
Source: 0001104659-25-019831
Chunk: 1

Company: MUSTANG BIO, INC.
Filing Date: 2025-03-03
Form: DEF 14C
Chunk 1
---
 (the “Investors”), and (B) that certain previously disclosed engagement
letter, dated as of October 23, 2024 (the “Engagement Letter,” and together with the Purchase Agreement, the “Agreements”),
with H.C. Wainwright & Co., LLC (the “Placement Agent,” and together with the Investors, the “Holders”), in
an amount equal to or in excess of 20% of the number of shares of common stock outstanding immediately prior to the issuance of such warrants
(collectively, the “Warrant Share Issuance”), as described in further detail in the Information Statement.

The accompanying Information
Statement is being furnished only to inform stockholders in accordance with Rule 14c-2 promulgated under the Securities Exchange Act of
1934, as amended (the “Exchange Act”), of the actions taken by Written Consent described in the Information Statement before
the Warrant Share Issuance takes effect. We are also furnishing the Information Statement to our stockholders in satisfaction of the notice
requirement under Section 228 of the General Corporation Law of the State of Delaware (“DGCL”). Because the Written Consent
of the Majority Holders satisfies all applicable stockholder voting requirements, the Board is not soliciting your proxy or consent in
connection with the matters discussed above. You are urged to read the Information Statement carefully and in its entirety for further
information regarding the Warrant Share Issuance.

This Information Statement
is first being mailed to you on or about March 3,
2025. The approval of the Warrant Share Issuance will become effective on the 20 day after this definitive information statement
is mailed to our stockholders.

This is not a notice of special meeting of stockholders and no stockholder meeting will be held to consider any matter which is described herein. We are not asking you for a consent or proxy and you are requested not to send us a consent or proxy.

| March 3, 2025 | By Order of the Board of Directors,                                    |
|:--------------|:-----------------------------------------------------------------------|
|               | /s/ Manuel Litchman, M.D.                                              |
|               | Manuel Litchman, M.D.                                                  |
|               | President, Chief Executive Officer and Interim Chief Financial Officer |

<div align='center'>MUSTANG BIO, INC.

95 Sawyer Road, Suite 110
Waltham, MA 02453

INFORMATION STATEMENT PURSUANT TO SECTION 14(C